Revised Hemp-CBD Status Report

Revised Hemp-CBD Status Report

How hemp and CBD companies are impacted by passage of the Farm Bill

Published: Thursday, July 11, 2019

Published in December 2018 and expanded in January 2019 and July 2019

The 2018 Farm Bill includes historic provisions that legalize hemp, the low THC cultivars of the Cannabis sativa L. species. When the president signed this landmark legislation into law, it changed how hemp and hemp-derived products like cannabidiol (CBD) are regulated in the U.S.

To help the herbal products industry understand the new regulatory landscape, AHPA produced a free Status Report and webinar to answer industry questions.

Free Status Report

AHPA worked with legal and industry experts to develop a new, free resource titled Status Report: Marketing of hemp and cannabidiol (CBD) products in the United States following passage of the 2018 Farm Bill.

This document provides concise and up-to-date information on the status of such operations and products as soon as this legislation is adopted as federal law and taking into account other current and relevant laws and regulations.

This status report was expanded in January 2019 to address state and tribal legal authority and the statement by FDA Commissioner Scott Gottlieb, M.D., on the use of hemp and its constituents in foods and dietary supplements.

Download Status Report here >>

On Demand Webinar

Recorded on Dec. 19, this webinar presents more than two hours of expert information on how the Farm Bill could affect companies that want to cultivate hemp crops or sell consumer goods that contain hemp and hemp-derived ingredients, including CBD. It also includes an extended Q&A session that answers to attendees' specific questions.

Webinar Details

  • Recorded: December 19, 2018
  • Duration: 2+ hours
  • Cost: $50 for members -- $100 for non members


Veteran herbal industry experts provide insiders' views of the evolving regulatory landscape for companies growing, manufacturing or selling hemp and products with hemp-derived ingredients, including CBD.

  • Michael McGuffin, President, AHPA
  • Jane Wilson, Director of Program Development, AHPA
  • Holly Johnson, Ph.D., Chief Science Officer, AHPA
  • Will Woodlee, Esq., Partner, Kleinfeld, Kaplan & Becker
  • Pete Evich, Vice President, Van Scoyoc Associates (Q&A)
  • Tony Young, Esq., Partner, Kleinfeld, Kaplan & Becker (Q&A)

More links

2020 Annual Fund Sponsors


AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.